Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025Cancer Immunology ImmunotherapyOpen Access

Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAdrien CostantiniPKPaul Takam KamgaEPElvire Pons‐Tostivint

Discussion

Loading...

Member takes

Overview

Evaluation of soluble PD-L1 levels predicts response and overall survival in patients with advanced NSCLC, suggesting its utility as a biomarker.

Key Points

  • Lower baseline soluble PD-L1 levels were linked to longer overall survival in patients with advanced NSCLC, particularly in those treated with immune checkpoint inhibitors.
  • Median overall survival for patients with low soluble PD-L1 was significantly higher at 18.0 months compared to 4.0 months for non-responders, indicating its prognostic value.
  • This observational analysis involved three prospective cohorts of patients, comparing those receiving immune checkpoint inhibitors to those treated with chemotherapy alone.
  • The results highlight the potential of soluble PD-L1 as a robust biomarker for assessing treatment response in advanced non-small cell lung cancer patients.

Cite This Study

Costantini et al. (2025) studied this question.

synapsesocial.com/papers/68af63d7ad7bf08b1eae3c35https://doi.org/10.1007/s00262-025-04126-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy2024 · 5 citations
  2. 2Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study2020 · 114 citations
  3. 3Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma2015 · 188 citations
  4. 4The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study2023 · 20 citations
  5. 5Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients2020 · 22 citations